Last reviewed 2026-04-20 · How we verify

Nethanol (FENBUTRAZATE)

Phase 2 active Small molecule

Nethanol (generic name: FENBUTRAZATE) is a fenbutrazate drug. It is currently in Phase 2 development.

Fenbutrazate is thought to work by modulating neurotransmitter activity in the brain.

Nethanol, also known as Fenbutrazate, is a small molecule drug in the fenbutrazate class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Nethanol is unclear, with unknown generic manufacturers and patent status. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to fully understand Nethanol's properties and potential uses.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FENBUTRAZATE
Drug class	fenbutrazate
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is a city with many different neighborhoods, each with its own unique culture and way of communicating. Fenbutrazate is like a special kind of traffic cop that helps regulate the flow of information between these neighborhoods, influencing how they work together to control mood and other functions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nethanol CI brief — competitive landscape report
Nethanol updates RSS · CI watch RSS

Frequently asked questions about Nethanol

What is Nethanol?

Nethanol (FENBUTRAZATE) is a fenbutrazate drug.

How does Nethanol work?

Fenbutrazate is thought to work by modulating neurotransmitter activity in the brain.

What is the generic name of Nethanol?

FENBUTRAZATE is the generic (nonproprietary) name of Nethanol.

What drug class is Nethanol in?

Nethanol belongs to the fenbutrazate class. See all fenbutrazate drugs at /class/fenbutrazate.

What development phase is Nethanol in?

Nethanol is in Phase 2.

Drug class: All fenbutrazate drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing